Expert Review of Anti-infective Therapy最新文献

Assessment of potentially unnecessary antibiotic use for suspected urinary tract infections in nursing homes using a simplified algorithm. 使用简化算法评估养老院疑似尿路感染可能不必要的抗生素使用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-26 DOI: 10.1080/14787210.2025.2456860

Carl Llor, Jonas Olsen, Jesper Lykkegaard, Marilena Anastasaki, Jette Nygaard Jensen, Jens Søndergaard, Valeria Antsupova, Davorina Petek, Malene Plejdrup Hansen, Marie Theut, Christos Lions, Lina Jaruseviciene, Ruta Radzeviciene, András Bálint, Helena Glasova, Jozef Glasa, Nina Sodja, Ana Moragas, Ramon Monfà, Ana García-Sangenís, Anna Kowalczyk, Georg Ruppe, Laura Vallejo-Torres, Marina Elistratova, Beatriz González López-Valcárcel, Greta Tsoulchai

{"title":"Assessment of potentially unnecessary antibiotic use for suspected urinary tract infections in nursing homes using a simplified algorithm.","authors":"Carl Llor, Jonas Olsen, Jesper Lykkegaard, Marilena Anastasaki, Jette Nygaard Jensen, Jens Søndergaard, Valeria Antsupova, Davorina Petek, Malene Plejdrup Hansen, Marie Theut, Christos Lions, Lina Jaruseviciene, Ruta Radzeviciene, András Bálint, Helena Glasova, Jozef Glasa, Nina Sodja, Ana Moragas, Ramon Monfà, Ana García-Sangenís, Anna Kowalczyk, Georg Ruppe, Laura Vallejo-Torres, Marina Elistratova, Beatriz González López-Valcárcel, Greta Tsoulchai","doi":"10.1080/14787210.2025.2456860","DOIUrl":"10.1080/14787210.2025.2456860","url":null,"abstract":"Background: Nursing home (NH) residents are frequently treated with antibiotics for urinary tract infections (UTIs), often due to overdiagnosis. The aim of this study was to evaluate the proportion of potentially unnecessary antibiotic use for suspected UTIs in NHs across eight European countries.Research design and methods: Over a three-month period (February to April 2024), NH professionals recorded information on all antibiotic treatments for UTIs using a specific registration chart. Based on medical literature and the expertise of the project consortium members, the authors developed and endorsed by consensus a simplified algorithm to assess unnecessary antibiotic use in residents without indwelling catheters.Results: The study, conducted across 110 NHs, included 2773 antibiotic-treated infections. Of these, 1158 (41.8%) were treated for UTIs. Among 975 UTI cases without catheters, 54.1% may have been unnecessarily treated. Over one-third involved nonspecific symptoms including poor general condition and changes in urine appearance, while specific urinary symptoms, such as incontinence (21.3%) and dysuria (20.8%), were less common. A trend toward greater, potentially unnecessary antibiotic use was observed when urine dipsticks were performed.Conclusions: The findings reveal potentially unnecessary antibiotic use. Further algorithm validation is needed to enhance diagnostic criteria, reduce overuse, and improve UTI management in NHs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":4.2,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-25 DOI: 10.1080/14787210.2025.2459722

Jun-Hyung Cho, So-Young Jin, Suyeon Park

{"title":"Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis.","authors":"Jun-Hyung Cho, So-Young Jin, Suyeon Park","doi":"10.1080/14787210.2025.2459722","DOIUrl":"https://doi.org/10.1080/14787210.2025.2459722","url":null,"abstract":"Background: Tegoprazan (TPZ), a potassium-competitive acid blocker with potent gastric acid-suppressing activity, may be a potential agent for treating Helicobacter pylori infection. The study aimed to evaluate the efficacy of TPZ-based therapy for H. pylori eradication compared with proton pump inhibitor (PPI)-based therapy.Research design and methods: A comprehensive literature search was conducted up to August 2024 using PubMed, Embase, and the Cochrane Library to investigate the beneficial effects of TPZ-based therapy for H. pylori eradication. The studies that evaluated the eradication rates between the TPZ- and PPI-based therapies were included. The authors conducted a meta-analysis to calculate the eradication rate and pooled risk ratio (RR) with a 95% confidence interval.Results: Seven studies involving 3200 patients were included. H. pylori eradication rates did not differ significantly between the TPZ- and PPI-based therapies based on the intention-to-treat (77.3% vs. 76.4%, p = 0.68; pooled RR = 1.01 [0.97-1.05]) and per-protocol (84.3% vs. 84.2%, p = 0.69; pooled RR = 1.01 [0.98-1.04]) analyses. Additionally, no significant difference was observed in the adverse drug events between TPZ- and PPI-based therapies (27.2% vs. 30.8%, p = 0.26; pooled RR = 0.91 [0.76-1.08]).Conclusions: H. pylori eradication and adverse drug event rates with TPZ- and PPI-based treatments were similar.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adult vaccinations against respiratory infections.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-23 DOI: 10.1080/14787210.2025.2457464

Antoni Torres, Catia Cilloniz, Marta Aldea, Guillermo Mena, José M Miró, Antoni Trilla, Ana Vilella, Rosario Menéndez

{"title":"Adult vaccinations against respiratory infections.","authors":"Antoni Torres, Catia Cilloniz, Marta Aldea, Guillermo Mena, José M Miró, Antoni Trilla, Ana Vilella, Rosario Menéndez","doi":"10.1080/14787210.2025.2457464","DOIUrl":"https://doi.org/10.1080/14787210.2025.2457464","url":null,"abstract":"Introduction: Lower respiratory infections have a huge impact on global health, especially in older individuals, immunocompromised people, and those with chronic comorbidities. The COVID-19 pandemic highlights the importance of vaccination. However, there are lower rates of vaccination in the adult population that are commonly due to a missed opportunity to vaccinate. Vaccination offers the best strategy to prevent hospitalization, complications, and death caused by lower respiratory infections.Areas covered: In this review, the authors provide an overview of the vaccines for lower respiratory infections in the adult population. The review highlights the available data about the impact of vaccines on preventing respiratory infections, focusing on the pneumococcal vaccine, influenza vaccine, COVID-19 vaccines, and respiratory syncytial virus (RSV) vaccines. The authors discuss the currently available scientific evidence on the role of vaccines against respiratory infections. Finally, the authors review the current recommendations for vaccines in the adult population.Expert opinion: Scientific evidence on the effectiveness of vaccines against respiratory infections is important. An efficient implementation of adult immunization strategies will provide an opportunity to decrease the global burden of lower respiratory infections. Recognizing the existing vaccines and their recommendations for the adult population is essential to achieve a high vaccination rate in the population.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

'Real-life' approach to applying PK/PD principles in infectious diseases clinical practice without access to prompt TDM. 在没有及时TDM的情况下，在传染病临床实践中应用PK/PD原则的“现实生活”方法。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-02 DOI: 10.1080/14787210.2024.2448727

Nicholas Geremia, Stefano Di Bella, Antonio Lovecchio, Jacopo Angelini, Antonio D'Avolio, Roberto Luzzati, Filippo Mearelli, Luigi Principe, Alessandra Oliva

{"title":"'Real-life' approach to applying PK/PD principles in infectious diseases clinical practice without access to prompt TDM.","authors":"Nicholas Geremia, Stefano Di Bella, Antonio Lovecchio, Jacopo Angelini, Antonio D'Avolio, Roberto Luzzati, Filippo Mearelli, Luigi Principe, Alessandra Oliva","doi":"10.1080/14787210.2024.2448727","DOIUrl":"https://doi.org/10.1080/14787210.2024.2448727","url":null,"abstract":"Introduction: Infectious disease treatments are transitioning from a one-size-fits-all approach to a more tailored approach. The increasing adoption of therapeutic drug monitoring (TDM) of antimicrobials is a clear example of this trend. Routine antimicrobial TDM in critically ill patients should be mandatory. Unfortunately, nowadays, only expert centers can provide it. Given the crucial nature of the first hours/days for achieving a favorable clinical outcome, empirical antibiotic therapy with an adequate choice of drug, dose and administration modalities is fundamental.Areas covered: We outline common scenarios encountered in clinical practice, such as in edematous patients, hypoalbuminemia, patients with liver and renal diseases, patients under renal replacement therapy or extracorporeal membrane oxygenation (ECMO), over or under-weight patients, in old adults and cases of infections caused by relatively high minimum inhibitory concentration (MIC) pathogens. Various clinical situations were analyzed with the help of the available literature (PubMed/MEDLINE/Google Scholar and books written by experts in pharmacology and infectious diseases).Expert opinion: In these different scenarios, we reported common examples of optimizing drug utilization to maximize therapeutic outcomes, reduce incorrect prescriptions and limit the emergence of antimicrobial resistance.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-16"},"PeriodicalIF":4.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii. 解开舒巴坦-杜罗巴坦：洞察其在对抗鲍曼不动杆菌引起的感染中的作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-19 DOI: 10.1080/14787210.2024.2440018

Yakun Fu, Tomefa E Asempa, Joseph L Kuti

{"title":"Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii.","authors":"Yakun Fu, Tomefa E Asempa, Joseph L Kuti","doi":"10.1080/14787210.2024.2440018","DOIUrl":"10.1080/14787210.2024.2440018","url":null,"abstract":"Introduction: Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against CRAB. The phase III randomized trial (ATTACK) demonstrated the safety and efficacy of sulbactam-durlobactam in combination with imipenem-cilastatin as background therapy in treating adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by CRAB.Areas covered: This review will discuss pharmacology, antimicrobial activity, pharmacokinetics/pharmacodynamics, clinical efficacy, safety, and therapeutic role of sulbactam-durlobactam. To gather relevant information, a literature search was performed using PubMed and Google Scholar electronic databases. Search terms used include sulbactam, sulbactam-durlobactam, ETX2514, Acinetobacter baumannii, Acinetobacter baumannii-calcoaceticus complex, CRAB, OXA-24, and OmpA. Additional information was obtained from the sulbactam-durlobactam FDA package insert and infectious diseases conference abstracts.Expert opinion: Sulbactam-durlobactam is a well-tolerated β-lactam-β-lactamase inhibitor combination agent with efficacy against CRAB. Given the limitations of alternative treatment options, sulbactam-durlobactam may also be considered as a treatment option for non-respiratory infections caused by CRAB, however further clinical studies are warranted.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"67-78"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting H3N2 influenza: advancements in treatment and vaccine strategies. 针对 H3N2 流感：治疗和疫苗策略的进展。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1080/14787210.2024.2443920

Shriyansh Srivastava, Nandani Jayaswal, Sachin Kumar, G S N Koteswara Rao, Roja Rani Budha, Aroop Mohanty, Rachana Mehta, Vasso Apostolopoulos, Sanjit Sah, D Katterine Bonilla-Aldana, Ricardo Ulloque-Badaracco, Alfonso J Rodriguez-Morales

{"title":"Targeting H3N2 influenza: advancements in treatment and vaccine strategies.","authors":"Shriyansh Srivastava, Nandani Jayaswal, Sachin Kumar, G S N Koteswara Rao, Roja Rani Budha, Aroop Mohanty, Rachana Mehta, Vasso Apostolopoulos, Sanjit Sah, D Katterine Bonilla-Aldana, Ricardo Ulloque-Badaracco, Alfonso J Rodriguez-Morales","doi":"10.1080/14787210.2024.2443920","DOIUrl":"10.1080/14787210.2024.2443920","url":null,"abstract":"Introduction: The emergence of the H3N2 influenza virus in 1968 marked a significant event as it crossed the species barrier. This shift led to a pandemic, resulting in the deaths of one million people globally and highlighting the virus's severe impact on older individuals due to antigenic drift.Area covered: This review comprehensively examines the virological characteristics, evolutionary trends, and global epidemiology of the Influenza A (H3N2) virus. It delves into vaccination strategies, antiviral interventions, and emerging diagnostic approaches. The impact of antigenic variation on vaccine design and effectiveness, seasonal outbreak patterns, and pandemic potential are explored. Additionally, the interplay between viral factors and host immune responses is assessed. Researchers are actively investigating innovative strategies to enhance vaccine efficacy against H3N2 mutations, such as precise antigenic material administration, controlled release patterns, understanding immune system mechanisms, and glycan engineering.Expert opinion: The ongoing mutational dynamics of the H3N2 virus necessitate regular vaccine updates, as advocated by the WHO. Research in the Western Pacific region underscores the need for heightened awareness and effective control strategies. Evaluating antiviral therapies and addressing drug resistance requires multidisciplinary approaches involving researchers, healthcare professionals, and policymakers. This comprehensive understanding of H3N2 is vital for improving public health interventions and preparing for future influenza challenges.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"5-18"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in Candida species isolated in Africa. 非洲念珠菌对细胞壁和质膜靶向抗真菌药物的耐药性机制。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-06 DOI: 10.1080/14787210.2024.2448844

Chibuike Ibe, Akaninyene Otu, Carolina Henritta Pohl

{"title":"Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in Candida species isolated in Africa.","authors":"Chibuike Ibe, Akaninyene Otu, Carolina Henritta Pohl","doi":"10.1080/14787210.2024.2448844","DOIUrl":"10.1080/14787210.2024.2448844","url":null,"abstract":"Introduction: There is a rise in the emergence of multidrug resistant fungal pathogens worldwide, including in Africa.Method: This systematic review summarized the published data on the mechanisms and epidemiology of antifungal resistance in Candida species in Africa between 2000 and early 2024.Result: Seventeen reports from seven African countries were analyzed but due to the paucity of data, the prevalence of antifungal resistant Candida isolates in Africa could not be estimated. However, a total of 1376 (out of 2812) resistant isolates were documented with South Africa reporting the most. Candida auris was the most reported species with multidrug and pandrug resistant strains documented in South Africa. Generally, azoles but not posaconazole or isavuconazole, resistance was reported. Fluconazole resistant isolates harbored Erg11 Y132F, VF125LA and K177A/R/N335S/E343D substitutions, MRR1 gain of function mutations or efflux pump protein over expression. Resistance to members of the echinocandin family was also reported and Fks1 S639P substitution was observed.Conclusion: The data highlight that the increasing Candida species resistance to cell wall and cell membrane active antifungals is a cause for serious concern in Africa. There is need to increase antifungal research capacity and mount epidemiological surveillance to determine the true scale of the problem.Prospero registration number: CRD42024550231.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"91-104"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypoalbuminemia as a predictor of severe dengue: a systematic review and meta-analysis. 低白蛋白血症作为严重登革热的预测因子：一项系统回顾和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-04 DOI: 10.1080/14787210.2024.2448721

Muhammed Shabil, Ganesh Bushi, Vasso Apostolopoulos, Tahani Alrahbeni, Khalid Al-Mugheed, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Neelima Kukreti, Sarvesh Rustagi, Yousef N Alhashem, Jawaher Alotaibi, Nawal A Al Kaabi, Tarek Sulaiman, Hussain R Alturaifi, Faryal Khamis, Ali A Rabaan, Prakasini Satapathy

{"title":"Hypoalbuminemia as a predictor of severe dengue: a systematic review and meta-analysis.","authors":"Muhammed Shabil, Ganesh Bushi, Vasso Apostolopoulos, Tahani Alrahbeni, Khalid Al-Mugheed, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Neelima Kukreti, Sarvesh Rustagi, Yousef N Alhashem, Jawaher Alotaibi, Nawal A Al Kaabi, Tarek Sulaiman, Hussain R Alturaifi, Faryal Khamis, Ali A Rabaan, Prakasini Satapathy","doi":"10.1080/14787210.2024.2448721","DOIUrl":"10.1080/14787210.2024.2448721","url":null,"abstract":"Introduction: Dengue fever is a significant health concern globally, especially in tropical regions. Identifying reliable markers for severe dengue, such as hypoalbuminemia, is crucial for early diagnosis and treatment.Methods: This review systematically explores the association between hypoalbuminemia and severe dengue. We searched databases including PubMed, Embase, Scopus, Cochrane, and Web of Science until 28 December 2023, focusing on studies that reported albumin levels in dengue patients. Our selection criteria aimed at observational studies, from which data extraction and quality assessment were performed using Nested- Knowledge and the Newcastle-Ottawa Scale.Results: A meta-analysis of 17 studies involving 974 severe and 18,496 non-severe dengue patients identified a standardized mean difference (SMD) in albumin levels of -1.625 g/dL (95% CI: -3.618 to -0.369). Subgroup analysis indicated more pronounced hypoalbuminemia in pediatric patients, with a pooled SMD of -1.08 g/dL (95% CI: -1.71 to -0.45). Our analysis demonstrated the link between hypoalbuminemia and severe dengue, indicating a significant pooled relative risk of 2.286, within 95% CI 1.308 to 3.996.Conclusions: The study confirms hypoalbuminemia as a significant predictor of severe dengue. Recognizing hypoalbuminemia in dengue patients can aid clinicians in forecasting the severity, potentially improving patient outcomes through targeted therapeutic strategies.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"105-118"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of adjuvants to improve antibiotic efficacy and reduce the burden of antimicrobial resistance. 使用佐剂提高抗生素疗效，减轻抗菌素耐药性负担。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-27 DOI: 10.1080/14787210.2024.2441891

Teresa Gil-Gil, Pablo Laborda, José Luis Martínez, Sara Hernando-Amado

{"title":"Use of adjuvants to improve antibiotic efficacy and reduce the burden of antimicrobial resistance.","authors":"Teresa Gil-Gil, Pablo Laborda, José Luis Martínez, Sara Hernando-Amado","doi":"10.1080/14787210.2024.2441891","DOIUrl":"10.1080/14787210.2024.2441891","url":null,"abstract":"Introduction: The increase in antibiotic resistance, together with the absence of novel antibiotics, makes mandatory the introduction of novel strategies to optimize the use of existing antibiotics. Among these strategies, the use of molecules that increase their activity looks promising.Areas covered: Different categories of adjuvants have been reviewed. Anti-resistance adjuvants increase the activity of antibiotics by inhibiting antibiotic resistance determinants. Anti-virulence approaches focus on the infection process itself; reducing virulence in combination with an antibiotic can improve therapeutic efficacy. Combination of phages with antibiotics can also be useful, since they present different mechanisms of action and targets. Finally, combining antibiotics with adjuvants in the same molecule may serve to improve antibiotics' efficacy and to overcome potential problems of differential pharmacokinetics/pharmacodynamics.Expert opinion: The successful combination of inhibitors of β-lactamases with β-lactams has shown that adjuvants can improve the efficacy of current antibiotics. In this sense, novel anti-resistance adjuvants able to inhibit efflux pumps are still needed, as well as anti-virulence compounds that improve the efficacy of antibiotics by interfering with the infection process. Although adjuvants may present different pharmacodynamics/pharmacokinetics than antibiotics, conjugates containing both compounds can solve this problem. Finally, already approved drugs can be a promising source of antibiotic adjuvants.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"31-47"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on actinomycetoma treatment: linezolid in the treatment of actinomycetomas due to Nocardia spp and Actinomadura madurae resistant to conventional treatments. 放线菌瘤治疗的最新进展：利奈唑胺用于治疗诺卡菌和硬膜放线菌引起的放线菌瘤，这些放线菌瘤对常规治疗具有耐药性。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-06 DOI: 10.1080/14787210.2024.2448723

Alexandro Bonifaz, Roxana S García-Sotelo, Fabiola Lumbán-Ramirez, Denisse Vázquez-González, José Iván Inclán-Reyes, Mario Eduardo Sierra-Garduño, Javier Araiza, David Chandler

{"title":"Update on actinomycetoma treatment: linezolid in the treatment of actinomycetomas due to Nocardia spp and Actinomadura madurae resistant to conventional treatments.","authors":"Alexandro Bonifaz, Roxana S García-Sotelo, Fabiola Lumbán-Ramirez, Denisse Vázquez-González, José Iván Inclán-Reyes, Mario Eduardo Sierra-Garduño, Javier Araiza, David Chandler","doi":"10.1080/14787210.2024.2448723","DOIUrl":"10.1080/14787210.2024.2448723","url":null,"abstract":"Introduction: Mycetoma is a chronic granulomatous infection, common throughout tropical regions, and is considered a neglected disease that mostly affects impoverished populations. Mycetoma is divided into eumycetoma, caused by fungi, and actinomycetoma, caused by filamentous bacteria. Clinical presentation is distinctive, and making the diagnosis is usually not difficult; however, access to safe and effective treatments is a major challenge. There is not a single best treatment, with the choice of treatment depending on etiology, severity and extent of disease, and patient comorbidities.Areas covered: The following topics regarding actinomycetoma are discussed. I) Background information on actinomycetoma, and etiology. II) Differences between actinomycetoma caused by Nocardia, and cutaneous nocardiosis. III) Review of the treatment options for actinomycetoma, caused by three species - Nocardia, Actinomadura, and Streptomyces. IV) Experience using linezolid in the treatment of mycetoma caused by Nocardia spp. and Actinomadura madurae.Expert opinion: Multiple treatment regimens for actinomycetoma were discussed according to the causative agent. Experience in using linezolid in combined therapy for actinomycetoma caused by Nocardia in which conventional treatment options failed was also presented. The first case report of treatment with linezolid for mycetoma caused by Actinomadura madurae is presented in this article.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"79-89"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0